Shi, Jianhua

Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial

Cheng, Y., Han, L., Wu, L., Chen, J., Sun, H., Wen, G., Ji, Y., Dvorkin, M., Shi, J., Pan, Z., et al. (2022) · JAMA

Lung Cancer Research StudiesCancer Immunotherapy and Biomarkers

Cited by 492

Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial

Zhou, C., Chen, G., Huang, Y., Zhou, J., Lin, L., Feng, J., Wang, Z., Shu, Y., Shi, J., Hu, Y., et al. (2021) · The Lancet Respiratory Medicine

Lung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers

Cited by 483

D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRASG12C in Patients With NSCLC: Phase 1 Study Results

Li, Z., Song, Z., Zhao, Y., Wang, P., Jiang, L., Gong, Y., Zhou, J., Jian, H., Dong, X., Zhuang, W., et al. (2023) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 88

Safety, Efficacy, and Pharmacokinetics of Rezivertinib (BPI-7711) in Patients With Advanced NSCLC With EGFR T790M Mutation: A Phase 1 Dose-Escalation and Dose-Expansion Study

Shi, Y., Zhao, Y., Yang, S., Zhou, J., Zhang, L., Chen, G., Fang, J., Zhu, B., Li, X., Shu, Y., et al. (2022) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 27

Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study

Shi, Y., Zhou, J., Zhao, Y., Zhu, B., Zhang, L., Li, X., Fang, J., Shi, J., Zhuang, Z., Yang, S., et al. (2023) · BMC Medicine

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 13

Efficacy and safety of bevacizumab biosimilar SIBP04 compared with bevacizumab (Avastin®) as first-line treatment for locally advanced or metastatic non-squamous non-small-cell lung cancer: A randomized, double-blind, phase 3 trial

Shi, Y., Bi, M., Li, Q., Wang, G., Chen, J., Li, M., Shi, J., Mei, J., Ji, Y., Xia, Q., et al. (2025) · Cancer Pathogenesis and Therapy

Lung Cancer Treatments and MutationsBiosimilars and Bioanalytical Methods

Cited by 2